During the past decade, University of Maryland Medical System conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 9 clinical trials were completed, i.e. on average, 36% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Maryland Medical System" #1 sponsor was "University of Maryland, Baltimore" with 6 trials, followed by "InSightec" with 5 trials sponsored, "Boston Scientific Corporation" with 3 trials sponsored, "ALX Oncology Inc." with 2 trials sponsored and "Edge Therapeutics Inc" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Maryland Medical System" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "Case Western Reserve University" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Johns Hopkins University" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 48 trials.

According to Clinical.Site data, the most researched conditions in "University of Maryland Medical System" are "Acute Ischemic Stroke" (2 trials), "Covid19" (2 trials), "Essential Tremor" (2 trials), "Head and Neck Cancer" (2 trials) and "Head and Neck Squamous Cell Carcinoma" (2 trials). Many other conditions were trialed in "University of Maryland Medical System" in a lesser frequency.

Most popular intervention types in "University of Maryland Medical System" are "Drug" (18 trials), "Device" (11 trials), "Other" (5 trials), "Procedure" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "EG-1962 (nimodipine microparticles)" (2 trials), "Enteral Nimodipine" (2 trials), "Evorpacept" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Maryland Medical System" are 36 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Maryland Medical System". undefined are not yet recruiting, 6 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in University of Maryland Medical System, 1 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in University of Maryland Medical System, 1 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 11 trials that are defined as “Not Applicable".